- Home
- ACR vs CNTB Comparison
ACR vs CNTB Comparison
Compare ACR & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACR | CNTB |
|---|---|---|
| Founded | 2005 | 2012 |
| Country | United States | United States |
| Employees | 4 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 146.1M | 135.7M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | ACR | CNTB |
|---|---|---|
| Price | $18.59 | $2.17 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $24.50 | $8.67 |
| AVG Volume (30 Days) | 16.2K | ★ 173.1K |
| Earning Date | 04-30-2026 | 08-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $64,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $19.59 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $17.06 | $0.75 |
| 52 Week High | $24.61 | $3.82 |
Technical Indicators
Market Signals| Indicator | ACR | CNTB |
|---|---|---|
| Relative Strength Index (RSI) | 33.26 | 40.93 |
| Support Level | $17.56 | $2.03 |
| Resistance Level | $19.64 | $2.68 |
| Average True Range (ATR) | 0.58 | 0.19 |
| MACD | -0.20 | -0.01 |
| Stochastic Oscillator | 4.58 | 8.48 |
Price Performance
Historical ComparisonAbout ACR ACRES Commercial Realty Corp.
ACRES Commercial Realty Corp is a commercial real estate investment trust that focuses on originating, holding, and managing commercial real estate (CRE) mortgage loans and equity investments in commercial real estate properties through direct ownership and joint ventures. The company invests in commercial real-estate-related assets, including whole loans, A notes, B notes, mezzanine loans, and mortgage-related securities, as well as commercial finance assets, which include other asset-backed securities, senior secured corporate loans, equipment leases and notes, trust preferred securities, debt tranches of collateralized debt obligations, and private equity investments mainly issued by financial institutions.
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.